fluorouracil has been researched along with Chronic Disease in 37 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or modified FOLFIRINOX (mFFX) is the first-line standard of care for metastatic pancreatic adenocarcinoma; effective and safe treatment strategies are needed as survival remains poor." | 5.69 | Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. ( Bai, X; Chen, Y; Fu, Q; Gao, S; Guo, C; Huang, D; Li, X; Liang, T; Que, R; Shen, Y; Wu, J; Xiao, W; Xue, X; Zhang, M; Zhang, Q; Zhang, X, 2023) |
| "The ulcers were mostly singular and measured 0." | 5.28 | Chronic ulcerations following topical therapy with 5-fluorouracil for vaginal human papillomavirus-associated lesions. ( Helmkamp, BF; Krebs, HB, 1991) |
| "In a search for alternative therapeutic methods other than corticosteroids and cytostatics, the effect of a dialyzable leukocyte extract (DLE), the antimetabolite 5-fluorouracil and the immunosuppressive agent cyclosporin A in corticosteroid-resistant idiopathic uveitis was studied." | 3.68 | [Alternatives to steroid therapy in chronic uveitis]. ( Fricke, B; Fricke, HJ; Friedrich, R; Illessy, A; Klein, S; Schröder, KD, 1990) |
| "The anticancer drugs, like 5-Fluorouracil, which are believed to interfere with enzyme protein synthesis in the exocrine cells of pancreas were administered intravenously to fifteen patients with various pancreatic diseases." | 3.65 | Clinical effects of anticancer drugs to pancreatic diseases as protein synthesis inhibitors. ( Kawamura, M; Kinami, Y; Miyazaki, I; Sakane, Y; Sugii, M, 1976) |
| "To establish a safe regimen of high-dose regional chemotherapy with NIPP using cisplatin in patients with incurable rectal cancer." | 2.79 | Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events. ( Kim, C; Kimata, R; Kumita, S; Murata, S; Onozawa, S; Tajima, H; Uchida, E, 2014) |
| "68 eyes with chronic open angle glaucoma were included in a randomised trial of intraoperative 5-FU versus placebo." | 2.70 | A randomised trial of the effect of intraoperative 5-FU on the outcome of trabeculectomy in east Africa. ( Khaw, PT; Yorston, D, 2001) |
| "Trials of treatment of acute pancreatitis with 5-fluorouracil were undertaken also in two cases with good result." | 2.65 | Cytostatics in the treatment of chronic and acute pancreatitis. ( Popiela, T; Turczynowski, W; Zajac, A, 1980) |
| "Risk of relapse of breast cancer depends largely on tumour features: size, grade and, particularly, lymph node status." | 2.42 | 21. The adjuvant treatment of breast cancer. ( Kelleher, M; Miles, D, 2003) |
| " Here, we investigated a safe and efficient dosing schedule of oxaliplatin in folinic acid, fluorouracil, and oxaliplatin (FOLFOX) regimen by monitoring total and free platinum concentrations in plasma." | 1.51 | Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report. ( Cai, X; Fang, W; Gu, Y; Li, X; Wang, D; Wang, J; Wang, Y; Xu, L; Zhao, F, 2019) |
| "Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed." | 1.46 | Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy. ( Horiuchi, T; Kimura, M; Maeda, T; Shirai, Y; Tanishima, H; Tominaga, T, 2017) |
| "Resiniferatoxin induced apoptosis in pancreatic cancer cells indicates that vanilloids may be useful in the treatment of human pancreatic cancer." | 1.33 | Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. ( Büchler, MW; di Mola, FF; Di Sebastiano, P; Felix, K; Friess, H; Giese, NA; Hartel, M; Hinz, U; Mascetta, G; Selvaggi, F; Wente, MN, 2006) |
| "We present a male patient with a perianal fistula of 30 years' duration that had been treated on several occasions." | 1.33 | [Mucinous adenocarcinoma on chronic perianal fistula treated by neoadjuvant chemoradiotherapy and laparoscopy-assisted abdominoperineal amputation]. ( Almendral, ML; Aranda, F; Echenique-Elizondo, M; Erro, JM; Ibáñez, J; Valenti, C, 2006) |
| "Complications included suprachoroidal hemorrhage in 7 (14%) of 49 eyes and intraoperative vitreous hemorrhage in 2." | 1.29 | Holmium laser sclerectomy. Success and complications. ( Bellows, AR; Hutchinson, BT; Lytle, R; Puliafito, CA; Schuman, JS; Stinson, WG, 1993) |
| "The ulcers were mostly singular and measured 0." | 1.28 | Chronic ulcerations following topical therapy with 5-fluorouracil for vaginal human papillomavirus-associated lesions. ( Helmkamp, BF; Krebs, HB, 1991) |
| "Histologic characteristics of squamous cell carcinoma include loss of cell organization and orientation, loss of intercellular bridges, presence of nuclear atypia and mitotic figures, and premature cell keratinization." | 1.27 | Skin lesions from sun exposure: a treatment guide. ( Gibson, LE; Perry, HO, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (27.03) | 18.7374 |
| 1990's | 12 (32.43) | 18.2507 |
| 2000's | 5 (13.51) | 29.6817 |
| 2010's | 9 (24.32) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, Q | 1 |
| Chen, Y | 1 |
| Huang, D | 1 |
| Guo, C | 1 |
| Zhang, X | 1 |
| Xiao, W | 1 |
| Xue, X | 1 |
| Zhang, Q | 1 |
| Li, X | 2 |
| Gao, S | 1 |
| Que, R | 1 |
| Shen, Y | 1 |
| Wu, J | 1 |
| Zhang, M | 1 |
| Bai, X | 1 |
| Liang, T | 1 |
| Wang, D | 1 |
| Xu, L | 1 |
| Fang, W | 1 |
| Cai, X | 1 |
| Wang, Y | 2 |
| Wang, J | 1 |
| Zhao, F | 1 |
| Gu, Y | 1 |
| Murata, S | 1 |
| Onozawa, S | 1 |
| Kim, C | 1 |
| Tajima, H | 1 |
| Kimata, R | 1 |
| Uchida, E | 1 |
| Kumita, S | 1 |
| Benson, AB | 1 |
| Pachman, DR | 1 |
| Qin, R | 1 |
| Seisler, DK | 1 |
| Smith, EM | 1 |
| Beutler, AS | 1 |
| Ta, LE | 1 |
| Lafky, JM | 1 |
| Wagner-Johnston, ND | 1 |
| Ruddy, KJ | 1 |
| Dakhil, S | 1 |
| Staff, NP | 1 |
| Grothey, A | 1 |
| Loprinzi, CL | 1 |
| Tanishima, H | 1 |
| Tominaga, T | 1 |
| Kimura, M | 1 |
| Maeda, T | 1 |
| Shirai, Y | 1 |
| Horiuchi, T | 1 |
| Atef, AM | 1 |
| Hamouda, MM | 1 |
| Mohamed, AH | 1 |
| Fattah, AF | 1 |
| Watayo, Y | 1 |
| Kuramochi, H | 1 |
| Hayashi, K | 1 |
| Nakajima, G | 1 |
| Kamikozuru, H | 1 |
| Yamamoto, M | 1 |
| Davison, SP | 1 |
| Sobanko, JF | 1 |
| Clemens, MW | 1 |
| Alejandro, LM | 1 |
| Behrendt, CE | 1 |
| Chen, K | 1 |
| Openshaw, H | 1 |
| Shibata, S | 1 |
| Kelleher, M | 1 |
| Miles, D | 1 |
| Hartel, M | 1 |
| di Mola, FF | 1 |
| Selvaggi, F | 1 |
| Mascetta, G | 1 |
| Wente, MN | 1 |
| Felix, K | 1 |
| Giese, NA | 1 |
| Hinz, U | 1 |
| Di Sebastiano, P | 1 |
| Büchler, MW | 1 |
| Friess, H | 1 |
| Ibáñez, J | 1 |
| Erro, JM | 1 |
| Aranda, F | 1 |
| Almendral, ML | 1 |
| Valenti, C | 1 |
| Echenique-Elizondo, M | 1 |
| Popiela, T | 1 |
| Turczynowski, W | 1 |
| Zajac, A | 1 |
| Takeda, K | 1 |
| Oritsu, M | 1 |
| Sakuta, M | 1 |
| O'Grady, JM | 1 |
| Juzych, MS | 2 |
| Shin, DH | 2 |
| Lemon, LC | 1 |
| Swendris, RP | 2 |
| Khatana, AK | 1 |
| Parrow, KA | 1 |
| Schuman, JS | 1 |
| Stinson, WG | 1 |
| Hutchinson, BT | 1 |
| Bellows, AR | 1 |
| Puliafito, CA | 1 |
| Lytle, R | 1 |
| Brestescher, C | 1 |
| Pautier, P | 1 |
| Farge, D | 1 |
| Yamashita, F | 1 |
| Tanaka, M | 1 |
| Fukumori, K | 1 |
| Ando, E | 1 |
| Yano, Y | 1 |
| Kato, O | 1 |
| Yamamoto, H | 1 |
| Fukuda, H | 1 |
| Kusaba, T | 1 |
| Tanikawa, K | 1 |
| Sata, M | 1 |
| Fellman, R | 1 |
| Budenz, D | 1 |
| Yorston, D | 1 |
| Khaw, PT | 1 |
| Meinardi, MT | 1 |
| Van Der Graaf, WT | 1 |
| Gietema, JA | 1 |
| Van Den Berg, MP | 1 |
| Sleijfer, DT | 1 |
| De Vries, EG | 1 |
| Haaksma, J | 1 |
| Boomsma, F | 1 |
| Van Veldhuisen, DJ | 1 |
| Dovzhanskiĭ, SI | 1 |
| Suvorov, AP | 1 |
| Breitbart, EW | 1 |
| Kinami, Y | 1 |
| Miyazaki, I | 1 |
| Kawamura, M | 1 |
| Sugii, M | 1 |
| Sakane, Y | 1 |
| Ottolenghi, F | 1 |
| Andreassi, L | 1 |
| Sbano, E | 1 |
| Fimiani, M | 1 |
| Krebs, HB | 1 |
| Helmkamp, BF | 1 |
| Patitsas, C | 1 |
| Rockwood, EJ | 1 |
| Meisler, DM | 1 |
| McMahon, JT | 1 |
| Wilson, RP | 1 |
| Steinmann, WC | 1 |
| Klein, S | 1 |
| Fricke, HJ | 1 |
| Fricke, B | 1 |
| Friedrich, R | 1 |
| Illessy, A | 1 |
| Schröder, KD | 1 |
| Rotstein, H | 1 |
| Baker, C | 1 |
| Alekseenko, AV | 1 |
| Fedorak, SS | 1 |
| Seniutovich, RV | 1 |
| Iftodiĭ, AG | 1 |
| Vasilov, VI | 1 |
| Gibson, LE | 1 |
| Perry, HO | 1 |
| Scott, D | 1 |
| Theologides, A | 1 |
| Markoff, N | 1 |
| Miller-Cranko, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity[NCT00316914] | Phase 3 | 104 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Neuropathic adverse events were assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | days (Median) |
|---|---|
| Ca/Mg | 81 |
| Placebo | 72 |
Neurotoxicity were assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ca/Mg | 46 |
| Placebo | 55.8 |
Acute neuropathic toxicities were measured using the Symptom Experience Diary and supplemental quality of life questions in the scale of 0 (no symptom) to 10 (worst symptom). The item score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Any score greater than 0 was considered having acute neuropathy. (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Ca/Mg | 88 |
| Placebo | 90 |
Neuropathic adverse events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Neurotoxicity evaluation grade: loss of deep tendon reflexes or paresthesia, including tingling, but not interfering with function (Grade 1); objective sensory alteration or paresthesia, including tingling, interfering with function, but not with activities of daily living (Grade 2); sensory alteration or paresthesia interfering with activities of daily living (Grade 3); permanent sensory losses that are disabling (Grade 4) (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Ca/Mg | 22 |
| Placebo | 41 |
Neurotoxicity were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Days (Median) |
|---|---|
| Ca/Mg | NA |
| Placebo | 18.1 |
Neurotoxicity was assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Days (Median) |
|---|---|
| Ca/Mg | NA |
| Placebo | NA |
Fatigue was measured by Brief Fatigue Inventory in the scale of 0 (no fatigue) to 10 (fatigue as bad as you can imagine). The item score was reversed and transformed into 0 (low quality of life (QOL)) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline. (NCT00316914)
Timeframe: Baseline and One month
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Fatigue NOW | Fatigue USUAL | Fatigue WORST | |
| Ca/Mg | 1.0 | 3.1 | 0.0 |
| Placebo | -2.8 | -1.6 | -1.6 |
Quality of Life (QOL) were measured using the Symptom Experience Diary and supplemental quality of life questions. Item score range: 0 (no symptom) to 10 (worst symptom). The score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline. (NCT00316914)
Timeframe: Baseline and One month
| Intervention | Units on a scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue WORST | Walking | Buttoning Shirt or Tying Laces | Diarrhea | Constipation | Abdominal Cramping | Bowel Problems with Normal Activity | Shortness of Breath (Week 2 - Baseline) | Swallowing (Week 2 - Baseline) | Numbness in Fingers, Toes (Week 2 - Baseline) | Tingling in Fingers, Toes (Week 2 - Baseline) | |
| Ca/Mg | 0.0 | -2.5 | -2.0 | -7.1 | -2.9 | -2.5 | -3.2 | -0.7 | -7.5 | -8.3 | -14.8 |
| Placebo | -1.6 | 0.2 | 0.4 | -10.4 | 0.4 | 1.3 | -9.1 | 2.1 | 2.1 | -9.6 | -20.4 |
Adverse Events were measured using CTCAE V3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal Infection | Acne NOS | Anemia | Anorexia | Clostridial Infection | Constipation | Dehydration | Diarrhea-No Colostom | Dry Skin | Erythema Multiforme | Fatigue | Hypercalcemia | Hyperglycemia | Hypermagnesemia | Hypersensitivity | Hypokalemia | Hypomagnesemia | Hyponatremia | Infection | Ischemia-Cerebral | Ischemia/Infarction | Laryngeal Discomfort | Leukopenia | Muscle Weakness | Myalgia | Nausea | Neuro-motor | Neuro-sensory | Neutropenia | Oral cavity MS CE | Pain-Abdominal | Pain-Chest | Pain-Headache | Rash/Desquamation | Skin Rxn-Hand/Foot | Stomatitis | Taste | Thrombocytopenia | Thrombosis | Urticaria | Vasc Access Complication | Vomiting | |
| Ca/Mg | 2 | 2 | 4 | 4 | 0 | 42 | 2 | 68 | 0 | 4 | 10 | 0 | 2 | 14 | 6 | 4 | 0 | 4 | 0 | 0 | 2 | 0 | 6 | 2 | 4 | 60 | 4 | 2 | 18 | 2 | 0 | 0 | 0 | 4 | 4 | 2 | 2 | 2 | 6 | 0 | 2 | 34 |
| Placebo | 0 | 2 | 4 | 2 | 2 | 47 | 6 | 73 | 2 | 0 | 25 | 2 | 0 | 18 | 0 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 10 | 0 | 0 | 71 | 4 | 12 | 33 | 0 | 8 | 2 | 4 | 0 | 2 | 2 | 2 | 2 | 4 | 2 | 0 | 33 |
3 reviews available for fluorouracil and Chronic Disease
| Article | Year |
|---|---|
21. The adjuvant treatment of breast cancer.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2003 |
The treatment of psoriasis.
Topics: Administration, Oral; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Bed Rest; Chroni | 1990 |
[Long-term therapy of liver diseases].
Topics: Aged; Anabolic Agents; Chronic Disease; Cortisone; Diet Therapy; Fatty Liver; Female; Fluorouracil; | 1972 |
10 trials available for fluorouracil and Chronic Disease
| Article | Year |
|---|---|
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Fluorouracil; Human | 2023 |
Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ca | 2014 |
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Calcium Compounds; Chronic Disease; C | 2015 |
Topical 5-fluorouracil for granular myringitis: a double-blinded study.
Topics: Acetic Acid; Administration, Topical; Adolescent; Adult; Anti-Infective Agents, Local; Antimetabolit | 2010 |
Cytostatics in the treatment of chronic and acute pancreatitis.
Topics: Acute Disease; Adult; Antineoplastic Agents; Chronic Disease; Clinical Trials as Topic; Cyclophospha | 1980 |
Trabeculectomy, phacoemulsification, and posterior chamber lens implantation with and without 5-fluorouracil.
Topics: Aged; Cataract Extraction; Chronic Disease; Conjunctiva; Fluorouracil; Follow-Up Studies; Glaucoma, | 1993 |
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over | 1998 |
A randomised trial of the effect of intraoperative 5-FU on the outcome of trabeculectomy in east Africa.
Topics: Antimetabolites; Chronic Disease; Fluorouracil; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Int | 2001 |
[Controlled clinical studies of a new wart medication based on fluorouracil].
Topics: Adolescent; Adult; Aged; Baths; Child; Child, Preschool; Chronic Disease; Clinical Trials as Topic; | 1979 |
Use of trabeculectomy with postoperative 5-fluorouracil in patients requiring extremely low intraocular pressure levels to limit further glaucoma progression.
Topics: Aged; Aged, 80 and over; Chronic Disease; Female; Fluorouracil; Follow-Up Studies; Glaucoma, Open-An | 1991 |
24 other studies available for fluorouracil and Chronic Disease
| Article | Year |
|---|---|
Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Colonic Neoplasms; Dose-Response Re | 2019 |
Colon cancer: the new chronic disease.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chronic Disease; Clinical Trials, Phase III | 2014 |
Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chronic Disease | 2017 |
Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronic Disease; Drug Monitoring; | 2010 |
Use of a collagen-glycosaminoglycan copolymer (Integra) in combination with adjuvant treatments for reconstruction of severe chest keloids.
Topics: Adult; Aged; Anti-Inflammatory Agents; Chondroitin Sulfates; Chronic Disease; Collagen; Combined Mod | 2010 |
Predicting acute and persistent neuropathy associated with oxaliplatin.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cohort | 2013 |
Vanilloids in pancreatic cancer: potential for chemotherapy and pain management.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell | 2006 |
[Mucinous adenocarcinoma on chronic perianal fistula treated by neoadjuvant chemoradiotherapy and laparoscopy-assisted abdominoperineal amputation].
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Anus Neoplasms; Chemotherapy, Adjuvant; C | 2006 |
[A case of coccidioidomycosis with central nervous system involvement].
Topics: Adult; Chronic Disease; Coccidioides; Coccidioidomycosis; Fluorouracil; Humans; Hydrocephalus; Male; | 1993 |
Needling revision of failed filtering blebs with adjunctive 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Fluorouracil; Follow-Up Studies; Glaucoma, | 1993 |
Holmium laser sclerectomy. Success and complications.
Topics: Aged; Choroid Hemorrhage; Chronic Disease; Fluorouracil; Follow-Up Studies; Glaucoma; Humans; Intrao | 1993 |
[Chemotherapy and cardiotoxicity].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Chronic Disease; Drug Synergism; Drug Therapy, C | 1995 |
Malignant glaucoma.
Topics: Anterior Chamber; Chronic Disease; Female; Fluorouracil; Follow-Up Studies; Glaucoma, Angle-Closure; | 1999 |
Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2002 |
[Use of fluorafur in the therapy of various chronic dermatoses].
Topics: Adult; Aged; Chronic Disease; Fluorouracil; Humans; Male; Middle Aged; Neurodermatitis; Psoriasis; S | 1977 |
Clinical effects of anticancer drugs to pancreatic diseases as protein synthesis inhibitors.
Topics: Acute Disease; Adult; Amylases; Chronic Disease; Cysts; Female; Fluorouracil; Humans; Male; Middle A | 1976 |
[Diffuse chronic mucocutaneous candidiasis: Effects of antimycotics in vitro].
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis, Cutaneous; Candidiasis, Oral; Child; Chroni | 1975 |
Chronic ulcerations following topical therapy with 5-fluorouracil for vaginal human papillomavirus-associated lesions.
Topics: Administration, Intravaginal; Adolescent; Adult; Aged; Cervix Uteri; Chronic Disease; Female; Fluoro | 1991 |
Infectious crystalline keratopathy occurring in an eye subsequent to glaucoma filtering surgery with postoperative subconjunctival 5-fluorouracil.
Topics: Chronic Disease; Eye Infections, Bacterial; Female; Fluorouracil; Glaucoma, Angle-Closure; Humans; K | 1991 |
[Alternatives to steroid therapy in chronic uveitis].
Topics: Adrenal Cortex Hormones; Adult; Cell Extracts; Child; Chronic Disease; Cyclosporins; Fluorouracil; H | 1990 |
[Treatment of pancreatitis by electrophoresis of cytostatics].
Topics: Acute Disease; Adult; Aged; Chronic Disease; Female; Fluorouracil; Humans; Iontophoresis; Male; Midd | 1988 |
Skin lesions from sun exposure: a treatment guide.
Topics: Acute Disease; Adult; Aged; Carcinoma, Squamous Cell; Cheilitis; Chronic Disease; Fluorouracil; Huma | 1985 |
Hepatoma, erythrocytosis and increased serum erythropoietin developing in long-standing hemochromatosis.
Topics: Aged; Animals; Biopsy, Needle; Carcinoma, Hepatocellular; Chronic Disease; Erythropoietin; Female; F | 1974 |
The use of 5 per cent fluoro-uracil for chronic solar skin damage.
Topics: Chronic Disease; Fluorouracil; Humans; Sunburn | 1972 |